Open AccessPulmonary Embolism in Covid-19 Pandemic: A Threat to Recovery of the Infected Patients
Author(s) -
Emmanuel Ifeanyi Obeagu,
Quratulain Babar,
C. C. N. Vincent,
Chukwuma J. Okafor,
Richard Eze,
Udunma Olive Chijioke,
Adaobi Maryann Ibekwe,
Immaculata Ogochukwu Uduchi
Publication year - 2021
Publication title -
journal of pharmaceutical research international
Language(s) - English
Resource type - Journals
ISSN - 2456-9119
DOI - 10.9734/jpri/2021/v33i42a32388
Subject(s) - medicine , pulmonary embolism , covid-19 , coronavirus , pandemic , disease , thrombosis , pathological , intensive care medicine , pathophysiology , immunology , infectious disease (medical specialty)
Severe Acute Respiratory Syndrome Coronavirus 2 is a new type of coronavirus that can cause Coronavirus Disease 2019 (Covid-19) and is associated with an increased risk of thrombosis-related pulmonary embolism. Globally, doctors have revised their management strategies for suspected and confirmed PD in patients with Coronavirus disease (Covid-19) in 2019. Choosing the right drug and the right dose requires consideration of potential comorbidities, which can be explained by the direct and indirect pathological consequences of Covid-19, complement activation, cytokine release, endothelial dysfunction, and the interaction between different types of blood cells. Discuss the pathophysiological events, therapeutic mortality strategies, risk factors and clinical management of patients with Covid-19 pulmonary embolism.